Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP7 | Q93009 | 11/20 | 0.50 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.47 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 3/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6516685 | 0.82 | CHEK1 (0.46) | RPS6KA3MEN1KMT2AGAA | |
| Bromide SCHEMBL28797051 | 0.80 | CHEK1 (0.45) | RPS6KA3MEN1KMT2AGAA | |
| SCHEMBL12988895 | 0.76 | MKNK1 (0.62) | USP7RPS6KA3MEN1KMT2AGAA | |
| SCHEMBL15667459 | 0.74 | SENP1 (0.54) | USP7SENP1MEN1KMT2AESR1 | |
| SCHEMBL28958011 | 0.73 | ESR1 (0.56) | USP7RPS6KA3SENP1MEN1KMT2A | |
| SCHEMBL7459372 | 0.72 | CHEK1 (0.45) | RPS6KA3MEN1KMT2AESR2 | |
| SCHEMBL28313349 | 0.72 | PIK3CA (0.51) | GAA | |
| SCHEMBL247903 | 0.71 | SENP1 (0.50) | USP7SENP1MGAMGAASI | |
| SCHEMBL68749 | 0.69 | SENP1 (0.48) | USP7SENP1MEN1KMT2AMGAM | |
| SCHEMBL9541037 | 0.69 | SENP1 (0.54) | USP7SENP1MGAMGAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008027442-A2 | ABUSE DETERRENT ORAL PHARMACEUTICAL FORMULATIONS OF OPIOID AGONISTS AND METHOD OF USE | THERAQUEST BIOSCIENCES, LLC (US) | 2008-03-06 | — | — | WO | claimed |
| WO-2008021394-A2 | PHARMACEUTICAL FORMULATIONS OF CANNABINOIDS AND METHOD OF USE | THERAQUEST BIOSCIENCES, LLC (US) | 2008-02-21 | — | — | WO | claimed |
| EP-3045043-A1 | EXTENDED RELEASE ORAL PHARMACEUTICAL COMPOSITIONS OF 3-HYDROXY-N-METHYLMORPHINAN AND METHOD OF USE | Relmada Therapeutics, Inc. (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-2448406-B1 | EXTENDED RELEASE ORAL PHARMACEUTICAL COMPOSITIONS OF 3-HYDROXY-N-METHYLMORPHINAN AND METHOD OF USE | RELMADA THERAPEUTICS INC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-9125833-B2 | Multimodal abuse resistant and extended release opioid formulations | RELMADA THERAPEUTICS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20120178771-A1 | Oral Pharmaceutical Compositions of Buprenorphine and Method of Use | RELMADA THERAPEUTICS, INC. | 2012-07-12 | — | — | US | disclosed |
| EP-2448406-A1 | EXTENDED RELEASE ORAL PHARMACEUTICAL COMPOSITIONS OF 3-HYDROXY-N-METHYLMORPHINAN AND METHOD OF USE | Relmada Therapeutics, Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| US-20120065221-A1 | Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use | THERAQUEST BIOSCIENCES, INC. (PA) | 2012-03-15 | — | — | US | disclosed |
| EP-2405754-A1 | MODIFIED RELEASE PHARMACEUTICAL COMPOSITIONS OF BUPRENORPHINE | Theraquest Biosciences, Inc. (US) | 2012-01-18 | — | — | EP | disclosed |
| US-20110097395-A1 | Oral Pharmaceutical Compositions of Buprenorphine and Method of Use | RELMADA THERAPEUTICS, INC. | 2011-04-28 | — | — | US | disclosed |
| EP-2262367-A2 | ORAL PHARMACEUTICAL COMPOSITIONS OF BUPRENORPHINE AND METHOD OF USE | Theraquest Biosciences, Inc. (US) | 2010-12-22 | — | — | EP | disclosed |
| US-20100249045-A1 | Multimodal Abuse Resistant and Extended Release Opioid Formulations | THERAQUEST BIOSCIENCES, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| WO-2010104494-A1 | MODIFIED RELEASE PHARMACEUTICAL COMPOSITIONS OF BUPRENORPHINE | THERAQUEST BIOSCIENCES, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010099508-A1 | EXTENDED RELEASE ORAL PHARMACEUTICAL COMPOSITIONS OF 3-HYDROXY-N-METHYLMORPHINAN AND METHOD OF USE | THERAQUEST BIOSCIENCES, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| WO-2009114118-A2 | ORAL PHARMACEUTICAL COMPOSITIONS OF BUPRENORPHINE AND METHOD OF USE | THERAQUEST BIOSCIENCES, INC. (US) | 2009-09-17 | — | — | WO | disclosed |
| WO-2008134071-A1 | MULTIMODAL ABUSE RESISTANT EXTENDED RELEASE FORMULATIONS | THERAQUEST BIOSCIENCES, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008027442-A2 | ABUSE DETERRENT ORAL PHARMACEUTICAL FORMULATIONS OF OPIOID AGONISTS AND METHOD OF USE | THERAQUEST BIOSCIENCES, LLC (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008024408-A2 | PHARMACEUTICAL FORMULATIONS OF CANNABINOIDS FOR APPLICATION TO THE SKIN AND METHOD OF USE | THERAQUEST BIOSCIENCES, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024490-A2 | ORAL PHARMACEUTICAL FORMULATIONS OF ABUSE DETERRENT CANNABINOIDS AND METHOD OF USE | THERAQUEST BIOSCIENCES, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008021394-A2 | PHARMACEUTICAL FORMULATIONS OF CANNABINOIDS AND METHOD OF USE | THERAQUEST BIOSCIENCES, LLC (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178771-A1 | Oral Pharmaceutical Compositions of Buprenorphine and Method of Use | OPRK1, OPRM1, OPRD1 | USP7 1906/4885RPS6KA3 4147/4885SENP1 4046/4885 |
| US-20110097395-A1 | Oral Pharmaceutical Compositions of Buprenorphine and Method of Use | CYP2B6, CYP3A5, OPRM1 | USP7 3407/4885RPS6KA3 4095/4885SENP1 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.